TWST · Twist Bioscience Corporation

Twist Bioscience delivered strong Q2 FY2026 results with revenue of $110.7 million, surpassing guidance and achieving 19% year-over-year growth, driven by robust performance in both DNA Synthesis and Protein Solutions (DSPS) at $53.3 million (+28% YoY, +4% sequentially) and NGS Applications at $57.4 million (+12% YoY, +9% sequentially). This marks the company's 13th consecutive quarter of sequential growth, reflecting consistent execution amid scaling operations. Gross margin expanded to 51.6% from 49.6% YoY, supported by operational efficiencies despite cost of revenues rising to $53.6 million. R&D expenses declined to $19.7 million from $23.9 million, aiding cost control, though SG&A increased to $76.1 million and a $7.2 million net litigation settlement charge contributed to a wider net loss of $44.0 million ($0.71 per share) versus $39.3 million ($0.66 per share) last year. Adjusted EBITDA improved slightly to $(13.3) million from $(14.8) million. CEO Emily Leproust highlighted momentum across the portfolio, with focus on scalable growth toward profitability. Management raised full-year revenue guidance to $442-447 million (17-19% growth), up from $435-440 million, and expects gross margin above 52%, Q3 revenue of $114-115 million (~19% YoY growth at midpoint), and adjusted EBITDA breakeven in Q4. Business highlights include shipping to 2,583 customers (+6% YoY), 300,000 genes (+32% YoY), new bispecific licensing with Invenra, AWS partnership, and launches of library preparation kits. Cash stood at $172 million as of March 31, 2026, providing runway amid $676 million total assets.